The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Butenafin     N-methyl-N-(naphthalen-1- ylmethyl)-1-(4...

Synonyms: Butenafina, Mentax, butenafine, Butenafinum, Mentax-TC, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Butenafine hydrochloride


High impact information on Butenafine hydrochloride

  • However, these isolates were fully cross resistant to several other known squalene epoxidase inhibitors, including naftifine, butenafine, tolnaftate, and tolciclate, suggesting a target-specific mechanism of resistance [6].
  • In patients with tinea cruris or tinea corporis who received once-daily butenafine 1% for 2 weeks, the mycological and overall cure rates continued to increase for up to 4 weeks after treatment cessation [7].
  • The excellent therapeutic efficacy of butenafine on experimental dermatophytosis may be attributed to its low MIC and good penetration and distribution in the horny layer and hair follicles, where fungi reside [1].
  • The results suggest that the direct membrane-damaging effect of butenafine may play a major role in its anticandidal activity and that the drug-induced alteration in the cellular sterol composition renders the cell membrane more susceptible to the membrane-damaging effect of this drug [8].
  • RESULTS: All three antifungals demonstrated comparable activity against the dermatophytes tested, with a MIC range of 0.03-0.25 micro g/ml for ciclopirox, < 0.001-0.25 micro g/ml for econazole and 0.03-0.25 micro g/ml for butenafine [9].

Chemical compound and disease context of Butenafine hydrochloride

  • CONCLUSION: The benzylamine antifungal agent butenafine demonstrates inherent anti-inflammatory properties, in vivo, as demonstrated by reduced cutaneous erythema response after UVB irradiation [3].
  • Eighty patients, diagnosed clinically to have tinea cruris or localized tinea corporis and confirmed on KOH examination, were randomly assigned to one of the two treatment groups in a double-blind manner; butenafine once daily for 2 weeks or clotrimazole twice daily for 4 weeks [10].

Associations of Butenafine hydrochloride with other chemical compounds


Analytical, diagnostic and therapeutic context of Butenafine hydrochloride


  1. Anti-Trichophyton mentagrophytes activity and percutaneous permeation of butenafine in guinea pigs. Arika, T., Hase, T., Yokoo, M. Antimicrob. Agents Chemother. (1993) [Pubmed]
  2. Effects of butenafine hydrochloride, a new benzylamine derivative, on experimental dermatophytosis in guinea pigs. Arika, T., Yokoo, M., Hase, T., Maeda, T., Amemiya, K., Yamaguchi, H. Antimicrob. Agents Chemother. (1990) [Pubmed]
  3. The antifungal agent butenafine manifests anti-inflammatory activity in vivo. Nahm, W.K., Orengo, I., Rosen, T. J. Am. Acad. Dermatol. (1999) [Pubmed]
  4. Treatment of toenail onychomycosis with 2% butenafine and 5% Melaleuca alternifolia (tea tree) oil in cream. Syed, T.A., Qureshi, Z.A., Ali, S.M., Ahmad, S., Ahmad, S.A. Trop. Med. Int. Health (1999) [Pubmed]
  5. Butenafine: an update of its use in superficial mycoses. Gupta, A.K. Skin Therapy Lett. (2002) [Pubmed]
  6. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Mukherjee, P.K., Leidich, S.D., Isham, N., Leitner, I., Ryder, N.S., Ghannoum, M.A. Antimicrob. Agents Chemother. (2003) [Pubmed]
  7. Butenafine. McNeely, W., Spencer, C.M. Drugs (1998) [Pubmed]
  8. Two mechanisms of butenafine action in Candida albicans. Iwatani, W., Arika, T., Yamaguchi, H. Antimicrob. Agents Chemother. (1993) [Pubmed]
  9. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria. Kokjohn, K., Bradley, M., Griffiths, B., Ghannoum, M. International journal of dermatology. (2003) [Pubmed]
  10. Comparative efficacy of topical 1% butenafine and 1% clotrimazole in tinea cruris and tinea corporis: a randomized, double-blind trial. Singal, A., Pandhi, D., Agrawal, S., Das, S. The Journal of dermatological treatment. (2005) [Pubmed]
  11. One-week therapy with twice-daily butenafine 1% cream versus vehicle in the treatment of tinea pedis: a multicenter, double-blind trial. Savin, R., De Villez, R.L., Elewski, B., Hong, S., Jones, T., Lowe, N., Lucky, A., Reyes, B., Stewart, D., Willis, I. J. Am. Acad. Dermatol. (1997) [Pubmed]
  12. Butenafine hydrochloride: for the treatment of interdigital tinea pedis. Syed, T.A., Maibach, H.I. Expert opinion on pharmacotherapy. (2000) [Pubmed]
  13. Six novel antimycotics. Rubin, A.I., Bagheri, B., Scher, R.K. American journal of clinical dermatology. (2002) [Pubmed]
WikiGenes - Universities